Retatrutide vs tirzepatide vs semaglutide: a plain-English comparison
Three molecules, three different receptor maps, three different stories on the FDA timeline.
TL;DR
- Semaglutide hits one receptor; tirzepatide hits two; retatrutide hits three.
- In published trials, more receptors generally meant more weight reduction on average.
- Semaglutide and tirzepatide are FDA-approved under brand names; retatrutide is still in late-stage trials.
What it is
Each of these three molecules is a peptide that mimics one or more of the body’s natural gut and pancreatic hormones. Semaglutide (Ozempic, Wegovy) mimics GLP-1 — the gut hormone released after eating that signals fullness. Tirzepatide (Mounjaro, Zepbound) mimics GLP-1 and GIP — a second gut hormone that affects insulin and fat handling. Retatrutide mimics all three: GLP-1, GIP, and glucagon — a third hormone that, paradoxically, can speed up energy expenditure when used at carefully tuned levels. Picture them as one-, two-, and three-key keychains, each opening more doors in the metabolic system.
How it works
After you eat, your gut sends two main fullness signals: GLP-1 and GIP. Your liver also responds to glucagon, the hormone that asks for stored sugar. These three signals together regulate appetite, blood sugar, and how readily fat is burned. Semaglutide pulls one lever — the GLP-1 lever. Tirzepatide pulls two. Retatrutide pulls all three. The third lever (glucagon) is the most counterintuitive — at the right level, it raises energy expenditure rather than just lowering intake. Adding levers does not always add safety, which is why every step up in receptor coverage requires more trial data.
Who asks about it
People come to this comparison when they are weighing options after a clinician evaluation, when a current GLP-1 has plateaued, or when they have read trial headlines and want to know how the molecules actually differ at the receptor level. The receptor map is the cleanest way to keep them straight.
What the research says
In phase 3 SURMOUNT-1, tirzepatide produced an average weight reduction of about 21% in adults with obesity at the highest dose (NEJM, 2022). Semaglutide STEP trial averages came in around 15%. Retatrutide’s phase 2 trial reported an average reduction of about 24% at the highest dose at 48 weeks; phase 3 data are pending (NEJM, 2023). Tirzepatide is FDA-approved for chronic weight management as Zepbound (2023) (FDA, 2023).
What to know before considering it
All three molecules require licensed clinician prescription and ongoing monitoring. Common side effects include nausea, vomiting, constipation, and injection-site reactions. Pancreatitis, gallbladder disease, and thyroid C-cell concerns appear in the prescribing information for the approved products. Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb 2026). Compounded versions of semaglutide and tirzepatide are not FDA-approved; the branded products are. Retatrutide is not commercially available in any form as of April 2026.
The Halftime POV
The headline numbers in these trials are real. They also describe trial averages, not individual patients. The honest version of this conversation includes side effects, the litigation backdrop, the cost differences between branded and compounded options, and the fact that the receptor map keeps expanding. Halftime Health’s job is to make that fuller picture visible — not to chase the biggest number.
Related reading:
- GLP-1: what this gut hormone actually does
- Retatrutide: what the triple-agonist literature shows
- Compounded semaglutide: what it is and how it differs from branded
FAQ
Q: What is the difference between semaglutide, tirzepatide, and retatrutide? A: Semaglutide hits one receptor (GLP-1). Tirzepatide hits two (GLP-1 and GIP). Retatrutide hits three (GLP-1, GIP, and glucagon). Each added receptor brings additional metabolic effects in the published trials.
Q: Which GLP-1 medication is most effective for weight? A: In published phase 2 and phase 3 trials, retatrutide showed the largest average weight reduction, followed by tirzepatide, then semaglutide. Trial averages do not predict individual results, and head-to-head trials in the same population are limited.
Q: Is retatrutide FDA-approved? A: No. As of April 2026, retatrutide is in late-stage clinical trials. It is not FDA-approved and is not commercially available. Semaglutide and tirzepatide are FDA-approved under their brand names; the compounded versions of these active ingredients are not FDA-approved.
Q: When will retatrutide be available? A: Phase 3 trial readouts are expected in 2026–2027. FDA review timelines vary; commercial availability would follow approval.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
